Please assess the completion status of the following clinical trial:

Trial Title: High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: Gestational age \<29 weeks; an echocardiographic evidence of significant PDA; an age of 12 to 24 hours; and RDS necessitating respiratory support.~-~Exclusion Criteria: Major congenital anomalies; life-threatening infection or hydrops fetalis; pulmonary hypertension; death before the conclusion of the first course of ibuprofen; urine output below 1 ml per kilogram of body weight per hour during the preceding 12 hours (with the exception of the first dose); a serum creatinine concentration of \>1.5 mg/dL (129 μmol per liter); a platelet count of \<50,000/mm3; a tendency to bleed, as revealed by hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools, and oozing from puncture sites.~-

- Gender: ALL
- Minimum Age: 12 Hours
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Infant treated with high dose ibuprofen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).